During the negotiations, the parties discussed expanding cooperation in the pharmaceutical sector, transferring modern drug production technologies, and localization. As the first stage of cooperation, they agreed to start producing "Daclatasvir" and "Sofosbuvir"—drugs used to treat the Hepatitis C virus—for the Uzbekistan market.
The project involves a step-by-step transfer of manufacturing technologies to Uzbekistan, involving Egyptian specialists, training local personnel, and adapting production facilities. Furthermore, the meeting explored the potential for localizing over a thousand types of medicines and the prospects for establishing insulin production in Uzbekistan.
Experts emphasize that this partnership will strengthen the national pharmaceutical industry, reduce import dependency, and provide the population with high-quality, affordable medicines, positioning Uzbekistan as a regional pharmaceutical hub.
